Parabilis’ US listing means the biotech IPO record has been broken twice in as many months as public listings continue hot ...

Ben Zercher is a Senior Analyst at PitchBook covering biotech & pharma. Parabilis Medicines just broke the record for the ...

The Cambridge, Massachusetts-based biotech priced 33.5 million shares at $20 each, topping the $625 million raised by Kailera ...

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking ...

A clinical trial update wiped out billions in the French company's market cap and raised questions over a potential takeover.

This year marks roughly fifty years since the modern biotechnology era began — an era defined by recombinant DNA, monoclonal ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

Mere months after obesity biotech Kailera Therapeutics netted the biggest initial public offering the sector has ever seen, ...

Tango Therapeutics stock soars after the biotech company announces initial data from its ongoing study on pancreatic cancer. An analyst calls the results ‘unprecedented.’ The medical device maker gave ...

A proposal to add biotechnology to the COINS Act follows two big deals involving Pfizer and Bristol Myers, and comes amid U.S ...

In 2023, ReNAgade Therapeutics launched with $300 million to exploit an “all in one” technology solution for RNA-based therapies. That same year, Tome Biosciences emerged from stealth with $213 ...

The largest-ever new stock sale for a venture-backed biotech company extends a streak of large IPOs in 2026 that’s now ...